Evidence map›Paper›PMID 37056910›Full record

ArticleJournal of inflammation research2023

Protective Effect of Qingchang Wenzhong Decoction on Colitis and Colitis-Related Carcinogenesis by Regulating Inflammation and Intestinal Fibrosis.

Yuan Cheng, Junxiang Li, Xiaosi Zhang, Yalan Li, Xiaojun Shi, Rui Shi, Tangyou Mao, Fushun Kou, Lei Shi

Open access · goldAbstract read
In one paragraph

Article in Journal of inflammation research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Yuan ChengGastroenterology Department, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, 100078, People's Republic of China.ORCID 0000-0003-1016-4060
Junxiang LiGastroenterology Department, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, 100078, People's Republic of China.
Xiaosi ZhangGastroenterology Department, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, 100078, People's Republic of China.
Yalan LiSchool of Life Sciences, Beijing University of Chinese Medicine, Beijing, 100029, People's Republic of China.
Xiaojun ShiGastroenterology Department, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, 100078, People's Republic of China.
Rui ShiGastroenterology Department, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, 100078, People's Republic of China.
Tangyou MaoGastroenterology Department, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, 100078, People's Republic of China.
Fushun KouGastroenterology Department, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, 100078, People's Republic of China.ORCID 0000-0003-1841-3324
Lei ShiGastroenterology Department, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, 100078, People's Republic of China.
Beijing University of Chinese Medicine · CNNanjing University of Chinese Medicine · CNTongji University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by mucosal inflammation, which may develop into ulcerative colitis-associated carcinogenesis (UCAC) with disease progression. Qingchang Wenzhong Decoction (QCWZD) is a classic and effective prescription for the clinical treatment of UC. QCWZD has been shown to alleviate intestinal mucosal injury in acute and chronic UC models. This study aimed to explore and then verify the pharmacological mechanisms of QCWZD in UC and UCAC therapy. Methods: In this study, approaches including microarray analysis, network pharmacology, and biological verification are employed to clarify the mechanism of QCWZD in the treatment of UC and UCAC. TCMSP, Swiss Target Prediction, and Similarity Ensemble Approach were used to investigate the active ingredients and targets of QCWZD. UC and UCAC valid targets were identified by the microarray data in the GEO database (GSE38713 and GSE47908). The core targets were obtained by PPI network and enriched by GO and KEGG. DSS and AOM/DSS mouse models were adopted to verify the above analysis results. Results: The enrichment analysis showed that the therapeutic targets of QCWZD enriched in blood circulation, cell adhesion molecules, and pathways of inflammation and cancer such as IL-17 signaling pathway and toll-like receptor signaling pathway were involved in the multiple synergies of QCWZD on UC and UCAC treatment. The results of experiments demonstrated that QCWZD can exert its effects on protecting the intestinal mucosal barrier, regulating inflammation and improving intestinal fibrosis in UC and UCAC and the main mechanism of QCWZD in treatment of UC and UCAC may be related to the activation of the IL-17, NF-κB and TLR4 signaling pathways. Conclusion: Our results indicated that QCWZD treated UC and UCAC via multiple targets and pathways and the IL-17, NF-κB and TLR4 signaling pathways may be highly involved in this process.

Indexed as

colitis-associated cancerintestinal fibrosisQCWZDulcerative colitisulcerative colitis-associated carcinogenesis

Identifiers

PMID37056910
PMCPMC10089279
OpenAlexW4362700639

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.